# Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma

> **NCT00667420** · PHASE1,PHASE2 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 17 (actual)

## Conditions studied

- Esophageal Adenocarcinoma
- Gastric Adenocarcinoma

## Interventions

- **DRUG:** panitumumab, epirubicin, oxaliplatin, xeloda

## Key facts

- **NCT ID:** NCT00667420
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-04
- **Primary completion:** 2011-06
- **Final completion:** 2014-06
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Closed due to slow accrual
- **Last updated:** 2014-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00667420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00667420, "Perioperative Panitumumab and Epirubicin, Oxaliplatin and Xeloda (EOX) in Patients With Gastroesophageal Adenocarcinoma". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00667420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*